Close Menu

NEW YORK – T2 Biosystems on Tuesday said that its preliminary first quarter revenues are expected to grow 22 to 44 percent year over year.

Due to the coronavirus pandemic, it also said that it will suspend its 2020 guidance, while adding it has licensed a SARS-CoV-2 test to be adapted to its rapid diagnostics platform.

For the quarter ending March 31, T2 estimates first quarter total revenue will be in the range of $2.2 million to $2.6 million compared to $1.8 million for the first quarter of 2019. The consensus Wall Street revenue estimate for Q1 is $3.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.